Sanofi (NYSE:SNY) reported today that its Toujeo Max SoloStar high-capacity insulin pen won FDA approval and will be available in the third quarter of this year.
The new device holds 900 units of long-acting insulin and delivers 160 units/mL of Toujeo insulin glargine in each injection, the insulin-maker touted.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi’s high-capacity insulin pen wins FDA nod appeared first on MassDevice.
from MassDevice https://ift.tt/2I6XdPT
Cap comentari:
Publica un comentari a l'entrada